How Much Does a Medical Robot Cost in 2026? Surgery, Rehab & Hospital Logistics Priced Out

Three Categories, Three Completely Different Economics

Medical robotics in 2026 is three separate markets operating under three different value frameworks. Analysing them together produces confusion; separating them produces clarity.

Surgical robots ($1M–2.5M): Revenue-generating capital equipment. The da Vinci Xi is expensive in isolation and extraordinarily economical when measured against the procedures it enables. The financial case is not cost reduction — it is revenue generation and competitive differentiation.

Rehabilitation robots ($80K–$500K): Clinical outcome assets. Hocoma Lokomat and exoskeleton platforms are not evaluated primarily on financial ROI. They are evaluated on patient outcomes: gait recovery speed, functional independence, therapy throughput. The financial case is made through reduced total cost of care.

Hospital logistics robots ($100K–$150K or RaaS): Operational cost reduction. Aethon TUG and Diligent Robotics Moxi are the clearest financial ROI case in the medical robot category — a direct substitution for logistics labour at significantly lower per-unit cost.

All three categories share one characteristic: none are available without institutional procurement. Every medical robot requires clinical evidence review, regulatory clearance (FDA 510(k) or CE marking), and vendor service contracts as conditions of deployment. This is not a consumer or SME category.

The da Vinci Economics: Razor and Blades at Scale

The Intuitive Surgical da Vinci Xi is the most commercially successful surgical robot ever built, with over 9,000 systems installed globally and more than 12 million procedures performed. Understanding its economics requires separating the hardware cost from the total business model.

da Vinci Xi: The Headline Numbers

The 10-Year Total Cost of Ownership

For a hospital performing 1,000 procedures per year at average instrument costs of $1,500/procedure:

The Revenue Side

At $15,000 average procedure revenue:

• 1,000 procedures/year × 10 years = $150,000,000 in procedure revenue
• Net margin after robot costs: $131,650,000 over 10 years

The hardware cost is paid back at approximately 133 procedures — roughly 6–8 weeks of operating time for a busy surgical programme. The instrument disposables are where Intuitive Surgical earns its margins. In Intuitive's 2024 annual report, instrument and accessory revenue represented approximately 59% of total company revenue. This is not a medical device company. It is a razor-and-blades business that happens to perform surgery.

The implication for hospital procurement: the decision to deploy a da Vinci is not primarily a cost decision. It is a strategic positioning decision about surgical programme development, surgeon recruitment, and patient acquisition. Hospitals without da Vinci systems lose minimally invasive surgery cases to competitors that have them.

For a direct comparison with the leading challenger platform, see da Vinci Xi vs CMR Versius.

CMR Versius: The Credible Challenger

CMR Surgical Versius is the most commercially credible competitor to da Vinci for hospital systems evaluating robotic surgery for the first time.

Estimated price: $600,000–$1,200,000 (modular configuration, not publicly disclosed)

Versius's strategic advantages over da Vinci in new deployments:

Modular architecture. Versius uses a multi-arm modular system where each arm is an independent unit. Hospitals can deploy fewer arms initially and add capacity as procedure volume grows, without committing to the full capital cost upfront.

Lower switching cost for new adopters. For hospitals without existing da Vinci infrastructure, surgeon training programmes, or Intuitive service relationships, the switching cost argument that protects da Vinci in established installations does not apply. Versius is the rational first-mover choice for new robotic surgery programmes.

Growing UK and EU presence. CMR Surgical has deployed Versius across NHS trusts and European hospital groups as an alternative to the da Vinci price premium. The NHS procurement framework, with its emphasis on total cost of ownership over 10-year contracts, has favoured Versius's lower entry cost.

For established da Vinci programmes, the switching cost is real and substantial — surgeon retraining, consumable stock changeover, service contract transitions. For new programmes, the calculus is more open.

Stryker Mako: Orthopaedic Precision

Stryker Mako occupies a different segment from soft-tissue surgical robots — it is an orthopaedic-specific robotic arm assistance system for knee and hip replacement procedures.

Price: ~$1,000,000–$1,500,000 + annual service

Mako's value proposition is precision in bone preparation: CT-scan-based pre-operative planning, haptic feedback guidance that constrains the surgeon's cutting tool to the pre-planned resection boundary. Clinical data shows measurable improvements in implant positioning accuracy versus manual techniques.

The Mako business model mirrors da Vinci's: Stryker makes significant margin on the Triathlon and Trident implant systems used in Mako procedures. The robot drives implant attachment — hospitals using Mako are effectively locked into Stryker's implant portfolio for robotic cases.

Rehabilitation Robots: Clinical ROI, Not Financial ROI

Rehabilitation robots are evaluated differently from surgical systems. The primary value metric is clinical: does the robot improve patient outcomes? The financial case follows from outcomes, not from direct labour substitution.

Hocoma Lokomat — Robotic Gait Therapy

Price: ~$300,000–$500,000

Lokomat is the most widely researched rehabilitation robot in the world, with over 400 published clinical studies. It provides body-weight-supported treadmill training with robotic guidance for patients recovering from stroke, spinal cord injury, and traumatic brain injury.

Clinical evidence: Meta-analyses show Lokomat therapy produces statistically significant improvements in gait speed and walking distance compared to conventional manual gait therapy. The financial translation: faster functional recovery reduces inpatient days, reduces physiotherapy hours per patient, and increases rehabilitation unit throughput.

For a comparison of Lokomat against wearable exoskeleton alternatives, see Hocoma Lokomat vs ReWalk Personal 6.0 and Hocoma Lokomat vs Ekso Bionics EksoGT.

ReWalk Personal 6.0 — Personal Exoskeleton

Price: ~$80,000–$100,000

ReWalk is the only FDA-cleared exoskeleton for home use by spinal cord injury patients. At $80,000–$100,000, it is positioned as a personal mobility device rather than a clinical rehabilitation tool — the patient owns and uses the device independently outside of clinical settings.

Ekso Bionics EksoGT — Clinical Exoskeleton

Price: ~$100,000–$150,000

EksoGT is a clinic-based exoskeleton for stroke and spinal cord injury rehabilitation. Unlike ReWalk, it requires a trained therapist operator and is used in supervised clinical sessions. FDA cleared for stroke and spinal cord injury indications.

Rehabilitation ROI Summary

Hospital Logistics: The Clearest Financial Case in Medical Robotics

Hospital logistics robots — autonomous transport systems for medications, linens, lab specimens, and supplies — represent the most straightforward financial ROI case in the entire medical robot category.

Aethon TUG

Price: ~$100,000–$150,000 purchase, or ~$2,000–$3,000/month RaaS

Aethon TUG is the dominant hospital logistics robot platform with deployments in over 200 hospitals. TUG navigates autonomously through hospital corridors, uses elevators, and delivers medications, clean linens, and lab specimens on defined routes.

Diligent Robotics Moxi

Price: ~$3,000–$5,000/month (RaaS only)

Moxi is a socially intelligent hospital robot designed to handle fetch-and-retrieve tasks that consume nursing time: collecting supplies, stocking procedure rooms, delivering items between departments. Diligent's published data shows Moxi handles approximately 30% of the non-clinical tasks that nurses perform during a shift — freeing clinical staff for patient care.

For a direct comparison, see Aethon TUG vs Diligent Robotics Moxi.

Hospital Logistics ROI

At RaaS pricing of $3,000–$5,000/month, Moxi benchmarks at or below the fully-loaded cost of a single logistics FTE — while operating 24 hours a day, 7 days a week, without sick leave, overtime, or turnover costs. For a hospital deploying one Moxi unit against one FTE role, payback is effectively immediate. For multi-unit deployments against multiple roles, the economics scale directly.

The Geppetto Catalog Data

Across the 12 medical robots tracked in Geppetto's catalog — spanning surgical assistance, rehabilitation, and hospital logistics — prices range from $50,000 for rehabilitation and logistics platforms to $2,000,000 for full surgical systems. No medical robot category is available without institutional procurement: all require clinical evidence review, regulatory clearance (FDA 510(k) or CE marking), and vendor service contracts as conditions of deployment.

What the Jobs Index Says

Geppetto's Registered Nurse Jobs Index entry scores 25/100 on the automation risk scale — one of the lowest scores in the entire index, and that number is correct.

The 25 reflects a structural reality about nursing that is not going to change:

Clinical judgement is not automatable. Assessing a patient's condition, interpreting ambiguous symptoms, making treatment decisions in complex multi-comorbidity cases — these are knowledge-intensive tasks that current AI and robotics cannot perform reliably in the margin cases that matter most.

Physical care requires human presence. Patient positioning, wound care, comfort, emotional support, end-of-life care — the human relationship dimension of nursing is not a task to be optimised away. It is the core of what nursing is.

What medical robots actually do: They remove the non-clinical tasks that consume nursing time without adding clinical value — logistics, routine transport, equipment setup. Moxi handles supply retrieval so nurses can spend more time at the bedside. The Lokomat enables more intensive gait therapy without requiring a physiotherapist to physically support the patient's weight for hours.

Medical robots are a productivity multiplier for clinical staff, not a displacement mechanism. The 25/100 score reflects that accurately.

For the broader analysis, see Will Robots Replace Nurses? and Robot Augmentation, Not Replacement.

Procurement Reality: What the Buying Process Actually Looks Like

For any institution evaluating medical robots, the procurement process is categorically different from other capital equipment purchases.

Clinical evidence review. Every medical robot deployment requires review of the published clinical evidence base. For surgical robots, this means evaluating comparative outcomes data (complication rates, conversion rates, recovery times) against your current standard of care. For rehabilitation robots, this means evaluating peer-reviewed studies on the specific indication you are treating.

Regulatory clearance verification. Da Vinci, Mako, ReWalk, and EksoGT are FDA 510(k) cleared for specific indications. Deploying a medical robot outside its cleared indication creates regulatory and liability exposure. Verifying the scope of clearance is a pre-procurement requirement, not a post-deployment consideration.

Surgeon and therapist training. No medical robot is operational without trained clinical operators. Intuitive Surgical requires surgeons to complete a structured training programme before performing da Vinci procedures. Lokomat and exoskeleton platforms require physiotherapist certification. Training timelines and costs are procurement variables, not afterthoughts.

Service contract terms. Medical robots are mission-critical equipment in a regulated environment. A da Vinci system going offline before a scheduled surgical list is not a maintenance inconvenience — it is a patient care and revenue event. Service contract terms (response time, replacement equipment, software update obligations) are primary negotiating variables, not standard boilerplate.

Total cost of ownership modelling. The hardware purchase price is the smallest element of the 10-year cost for surgical systems. Any procurement decision made on hardware price alone is analytically incomplete.

For more on the current medical robot landscape, see Best Medical Robots 2026 and What Surgical Robots Actually Replace.

The Cricket's Take

> The da Vinci surgical system costs $2 million. At $15,000 per procedure, it pays back its hardware cost in approximately 133 procedures. A busy surgical programme does that in two months. The instrument disposables are where Intuitive Surgical makes its money — $700–$3,500 per procedure, forever. This is not a medical device company. It is a razor-and-blades business that happens to perform surgery.

The registered nurse Jobs Index score of 25/100 is not a consolation prize. It is an accurate assessment of what nursing is. Medical robots remove the logistics overhead that sits on top of clinical work. They do not touch the clinical work itself. Moxi fetching supplies so a nurse can spend more time with a patient is the correct use of this technology. Moxi replacing the nurse is not possible, not desirable, and not what any of these platforms are designed to do.

Frequently Asked Questions

How much does a surgical robot cost in 2026?

The Intuitive Surgical da Vinci Xi costs $1.5M–2.5M to purchase, with annual service contracts of $100,000–$170,000 and instrument disposable costs of $700–3,500 per procedure. CMR Surgical Versius is estimated at $600,000–1,200,000 with modular pricing not publicly disclosed. Stryker Mako for orthopaedic procedures costs approximately $1M–1.5M. All surgical robot deployments require FDA or CE regulatory clearance and structured clinical training programmes as pre-deployment conditions.

What is the total cost of ownership for a da Vinci surgical robot?

Over a 10-year horizon for a hospital performing 1,000 procedures per year, total da Vinci Xi ownership costs approximately $18.35M: $2M hardware, $1.35M in service contracts, and $15M in instrument disposables at an average of $1,500 per procedure. Against procedure revenue of $15,000 per case, the system generates $150M over the same period. The hardware cost is a minor element of the 10-year economics; instrument disposables represent the dominant ongoing cost and the core of Intuitive Surgical's business model.

How much does a hospital logistics robot cost?

Aethon TUG costs approximately $100,000–$150,000 to purchase, or $2,000–3,000 per month on a RaaS model. Diligent Robotics Moxi is available on RaaS only at approximately $3,000–5,000 per month. Both platforms benchmark at or below the fully-loaded annual cost of a single hospital logistics FTE ($45,000–60,000), while operating around the clock without overtime or turnover costs.

Are medical robots covered by hospital insurance or reimbursement?

In the United States, robotic surgery procedures are reimbursed through standard Medicare and private insurer DRG codes — the robotic assistance itself does not attract a separate reimbursement premium in most cases, though some insurers apply robotic surgery billing codes for specific procedures. The financial justification for surgical robots is therefore primarily competitive and volume-based, not reimbursement-differential based. Rehabilitation exoskeletons have limited insurance coverage; ReWalk has secured some Medicare and VA coverage for qualifying spinal cord injury patients.

Will robots replace nurses?

No. Geppetto's Jobs Index rates registered nursing at 25/100 on the automation risk scale — one of the lowest scores in the index. Medical robots remove non-clinical logistics tasks from nursing workflows; they do not and cannot perform clinical assessment, treatment decision-making, or the human relationship dimensions of patient care. Diligent Robotics Moxi and Aethon TUG are explicitly designed to handle supply transport and fetch tasks so that nursing staff can spend more time on direct patient care. The technology's design intent is augmentation, not displacement.

What regulatory approval do medical robots need?

In the United States, surgical robots and rehabilitation exoskeletons require FDA 510(k) premarket clearance, which requires demonstrating substantial equivalence to a predicate device and evidence of safety and effectiveness for the cleared indication. Hospital logistics robots (Moxi, TUG) operate under different frameworks as non-clinical devices. In the EU, medical robots require CE marking under the Medical Device Regulation (MDR 2017/745). Procurement without verifying the scope and status of regulatory clearance for the specific intended use is a compliance and liability risk.

Further Reading

• Wright's Law and Robot Cost Decline
• Robot Augmentation, Not Replacement